This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
About Zinforo

About Zinforo

OverviewExtended spectrum coverageDosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosingEfficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric SafetyClinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE studySupport & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Identifying a CAP patient who may benefit from Zinforo®Listen to Professor Antoni Torres as he discusses the challenges involved in treating community-acquired pneumonia.In CAP patients, initial antimicrobial therapy failure is associated with up to 5 days longer in hospital and 3x higher mortality2,8,9George, 70-year-old nursing home resident presented with fever, cough and sputum production*

Severity

  • PORT score IV (severe)​​​​​​​
    • 70-year-old male
    • RR >30/min
    • Temperature >40°C
    • Nursing home resident

History/comorbidities

  • History of smoking

Risk factors for difficult-to-treat infection

  • Age >65 years
  • Recurrent infection (hospitalised for pneumonia 3 months ago)
  • Previous antibiotic use
Marco presented with fever, cough and pleuritic chest pain and there has been no improvement with ceftriaxone*

Severity

  • PORT score IV (severe)
    • 78-year-old male
    • Chronic renal disease
    • Pulse >125 bpm
    • RR >30/min
    • No clinical improvement within 72 hours of ceftriaxone initiation

History/comorbidities

  • Renal insufficiency
  • Recent alcoholism

Risk factors for difficult-to-treat infection

  • Age >65 years
  • Medical comorbidities
  • Alcoholism
Marie presented with fever, dyspnoea and cough*

Severity

  • PORT score III (moderate)
    • 56-year-old female
    • PO2<90% (upon admission)
    • Blood glucose >250 mg/dL
    • Increasing oxygen requirements to maintain oxygen saturation

History/comorbidities

  • Mild asthma
  • Diabetes

Risk factors for difficult-to-treat infection

  • Recent antibiotic exposure for URTI within previous 3 months
When there’s no time to wait, clinical trial evidence supports the use of Zinforo in your CAP patients§3,4​​​​​​​

Learn about proven efficacy in CAP patients

Explore More Read several cSSTI patient profiles describing potential scenarios where Zinforo could be a treatment of choice. Access cSSTI patient profilesLoading To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.  View CAPTURE study profileLoading

*The examples described here are not actual patients, but fictitious representations of scenarios for which Zinforo could be considered.
§ Refer to SmPC for further information on Zinforo1

Abbreviations​​​​​​​

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; ICU, intensive care unit; RR, respiratory rate; URTI, upper respiratory tract infection; PORT, Pneumonia Patient Outcomes Research Team.​​​​​​​

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References

ZINFORO. Summary of Product CharacteristicsOtt SR, et al. Eur Respir J 2012;39:611–18File TM, et al. Clin Infect Dis 2010;51:1395–405Eckburg P, et al. Infect Dis Clin Pract 2012;51:1395–405Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7Ostermann H, et al. BMC Pulm Med 2014;14:36.Menéndez R, et al. Thorax 2004;59:960–5.
PP-ZFO-GBR-0231. September 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​